Biotech

All Articles

Ideaya bags option on Biocytogen bispecific ADC in $400M offer

.Ideaya Biosciences is wagering $400 million in biobucks that a bispecific antibody-drug conjugate (...

Takeda takes $140M loss on fallen short epilepsy drug, proclaims FDA operate

.We currently know that Takeda is actually intending to discover a course to the FDA for epilepsy me...

VBI Vaccines apply for insolvency, seeks resource purchase

.Immunology biotech VBI Injections is actually veering precariously near to the moment of truth, wit...

Celldex anti-cKIT antitoxin decrease hives in another period 2 research study

.It is actually hard to muscular tissue in on a room as affordable as immunology, however Celldex Re...

Boehringer provides to $1.3 B for gate inhibitor biotech

.Boehringer Ingelheim is actually providing to $1.3 billion for Nerio Therapeutics as well as a prec...

Ventyx's last hope for inflamed med sides in Crohn's breakdown

.Ventyx Biosciences' Crohn's ailment medicine carried out certainly not aid patients attain remissio...

Cognition's stage 2 beam records tarnish Alzheimer's prospect

.Knowledge Rehabs' stage 2 sparkle test has actually taken some of the radiance off the Alzheimer's ...

BMS centers bispecific months after filing to work phase 3 trial

.Bristol Myers Squibb has had a whiplash change of heart on its BCMA bispecific T-cell engager, stop...

Charles Baum takes control of Terremoto as chief executive officer

.Charles Baum, M.D., Ph.D., who managed Mirati Therapies' $ 5.8 billion purchase to Bristol Myers Sq...

Asarina to shut after efforts to partner Tourette's medication fall short

.After reaching out to more than 200 firms to partner a Tourette disorder treatment that presented t...